Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.
Sabnis RW.
ACS Med Chem Lett. 2023 Oct 19;14(11):1491-1492. doi: 10.1021/acsmedchemlett.3c00441. eCollection 2023 Nov 9.
PMID:37974944
Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.
Sabnis RW.
ACS Med Chem Lett. 2022 Mar 4;13(4):528-529. doi: 10.1021/acsmedchemlett.2c00085. eCollection 2022 Apr 14.
PMID:35450363
Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.
Sabnis RW.
ACS Med Chem Lett. 2022 Jul 29;13(8):1217-1218. doi: 10.1021/acsmedchemlett.2c00323. eCollection 2022 Aug 11.
PMID:35978687
Abdominal Pain Mimics.
Murali N, El Hayek SM.
Emerg Med Clin North Am. 2021 Nov;39(4):839-850. doi: 10.1016/j.emc.2021.07.003. Epub 2021 Sep 10.
PMID:34600641
Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.
Sabnis RW.
ACS Med Chem Lett. 2022 May 13;13(6):883-884. doi: 10.1021/acsmedchemlett.2c00193. eCollection 2022 Jun 9.
PMID:35707157
Hereditary Angioedema Agents.
[No authors listed]
2024 Jun 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–.
PMID:39047136
Adverse drug reactions of GLP-1 agonists: A systematic review of case reports.
Plasma Kallikrein Inhibitors as Potential Treatment for Diabetic Macular Edema, Retinal Vein Occlusion, Hereditary Angioedema and Other Related Diseases.
Abdel-Magid AF.
ACS Med Chem Lett. 2023 Jan 17;14(2):129-130. doi: 10.1021/acsmedchemlett.2c00526. eCollection 2023 Feb 9.
PMID:36793429
Angiotensin-Converting Enzyme Inhibitors and Other Medications Associated With Angioedema.